Role of interleukins in the pathogenesis of pulmonary fibrosis

Abstract Interleukins, a group of cytokines participating in inflammation and immune response, are proved to be involved in the formation and development of pulmonary fibrosis. In this article, we reviewed the relationship between interleukins and pulmonary fibrosis from the clinical, animal, as wel...

Full description

Bibliographic Details
Main Authors: Yi Xin She, Qing Yang Yu, Xiao Xiao Tang
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-021-00437-9
id doaj-c93691b3b151445eb7c4373250c3b9d1
record_format Article
spelling doaj-c93691b3b151445eb7c4373250c3b9d12021-03-21T12:49:46ZengNature Publishing GroupCell Death Discovery2058-77162021-03-017111010.1038/s41420-021-00437-9Role of interleukins in the pathogenesis of pulmonary fibrosisYi Xin She0Qing Yang Yu1Xiao Xiao Tang2State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical UniversityState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical UniversityState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical UniversityAbstract Interleukins, a group of cytokines participating in inflammation and immune response, are proved to be involved in the formation and development of pulmonary fibrosis. In this article, we reviewed the relationship between interleukins and pulmonary fibrosis from the clinical, animal, as well as cellular levels, and discussed the underlying mechanisms in vivo and in vitro. Despite the effects of interleukin-targeted treatment on experimental pulmonary fibrosis, clinical applications are lacking and unsatisfactory. We conclude that intervening in one type of interleukins with similar functions in IPF may not be enough to stop the development of fibrosis as it involves a complex network of regulation mechanisms. Intervening interleukins combined with other existing therapy or targeting interleukins affecting multiple cells/with different functions at the same time may be one of the future directions. Furthermore, the intervention time is critical as some interleukins play different roles at different stages. Further elucidation on these aspects would provide new perspectives on both the pathogenesis mechanism, as well as the therapeutic strategy and drug development.https://doi.org/10.1038/s41420-021-00437-9
collection DOAJ
language English
format Article
sources DOAJ
author Yi Xin She
Qing Yang Yu
Xiao Xiao Tang
spellingShingle Yi Xin She
Qing Yang Yu
Xiao Xiao Tang
Role of interleukins in the pathogenesis of pulmonary fibrosis
Cell Death Discovery
author_facet Yi Xin She
Qing Yang Yu
Xiao Xiao Tang
author_sort Yi Xin She
title Role of interleukins in the pathogenesis of pulmonary fibrosis
title_short Role of interleukins in the pathogenesis of pulmonary fibrosis
title_full Role of interleukins in the pathogenesis of pulmonary fibrosis
title_fullStr Role of interleukins in the pathogenesis of pulmonary fibrosis
title_full_unstemmed Role of interleukins in the pathogenesis of pulmonary fibrosis
title_sort role of interleukins in the pathogenesis of pulmonary fibrosis
publisher Nature Publishing Group
series Cell Death Discovery
issn 2058-7716
publishDate 2021-03-01
description Abstract Interleukins, a group of cytokines participating in inflammation and immune response, are proved to be involved in the formation and development of pulmonary fibrosis. In this article, we reviewed the relationship between interleukins and pulmonary fibrosis from the clinical, animal, as well as cellular levels, and discussed the underlying mechanisms in vivo and in vitro. Despite the effects of interleukin-targeted treatment on experimental pulmonary fibrosis, clinical applications are lacking and unsatisfactory. We conclude that intervening in one type of interleukins with similar functions in IPF may not be enough to stop the development of fibrosis as it involves a complex network of regulation mechanisms. Intervening interleukins combined with other existing therapy or targeting interleukins affecting multiple cells/with different functions at the same time may be one of the future directions. Furthermore, the intervention time is critical as some interleukins play different roles at different stages. Further elucidation on these aspects would provide new perspectives on both the pathogenesis mechanism, as well as the therapeutic strategy and drug development.
url https://doi.org/10.1038/s41420-021-00437-9
work_keys_str_mv AT yixinshe roleofinterleukinsinthepathogenesisofpulmonaryfibrosis
AT qingyangyu roleofinterleukinsinthepathogenesisofpulmonaryfibrosis
AT xiaoxiaotang roleofinterleukinsinthepathogenesisofpulmonaryfibrosis
_version_ 1724210112202014720